Digestive Diseases and Sciences

, Volume 49, Issue 11–12, pp 1786–1790 | Cite as

Abnormality of Peptide YY and Pancreatic Polypeptide Immunoreactive Cells in Colonic Mucosa of Patients with Colonic Inertia

  • Rong Hua Zhao
  • Khurrum M. Baig
  • Steven D. Wexner
  • Sherry Woodhouse
  • Jay J. Singh
  • Eric G. Weiss
  • Juan J. Nogueras


The etiopathology of colonic inertia remains unclear. Current studies show that pancreatic polypeptide-fold family members can serve as regulators of colonic motility and transit. Thus, the cells containing these peptides on colonic mucosa could be abnormal in patients with colonic inertia. We aimed to evaluate the immunocytochemical staining of peptide YY (PYY) and pancreatic polypeptide (PP) immunoreactive cells, and detect if alteration of these cells relates to an increase in enterochromaffin cells (EC) demonstrated by chromogranin A (CgA), in the colonic mucosa of patients with colonic inertia. Nineteen consecutive patients (18 female, 1 male; age, 43.7 ± 11.5 years) who underwent subtotal colectomy for colonic inertia were assessed. The control group consisted of 15 patients (all female; age, 50.7 ± 12.5 years) who underwent colonoscopic biopsies from the right and left colon for indications other than constipation, inflammatory bowel diseases, diarrhea, or neoplasm. Hollande’s-fixed, paraffin-embedded tissues of both right and left colons were collected. Immunocytochemical staining of PYY, PP, or CgA was performed on 4-μm tissue sections with the respective primary rabbit antibody, the biotinylated secondary antibody, and enzyme-labeled streptavidin. The average number of positive cells per microscopic field (200×) was calculated. Positive cells were classified as strongly, moderately, and weakly staining. The proportion of the variously stained cells is expressed as the percentage of the entire positive cell population. On both sides of the colon, the percentages of strongly and moderately stained PYY positive cells were higher in the patient group compared to the controls (right side, 10.6 and 27.3 vs. 6.1 and 18.7%, respectively; left side, 9.4 and 23.9 vs. 6.2 and 23.1%, respectively) (P&<0.01). Furthermore, in the patients with colonic inertia, the percentages of strongly and moderately stained PYY-positive cells were higher in the right-side colon than in the left (P&<0.01). There was no difference in the number of PYY-positive cells between the patients and the controls. PP-positive cells were very rare in all specimens and were found in 7 of 19 cases (36.84%) in the right-side colon and 16 of 19 (84.21%) in the left-side colon in the patient group (P&<0.01, left vs. right). In contrast, the number of EC in the left colon of patients (16.8± 10.2) was significantly higher than that in the right side (9.4± 6.0) (P&<0.01) or that in the left side in the control group (10.4± 6.0) (P&<0.05). We conclude that in the colonic mucosa of patients with colonic inertia, PYY-positive cells present with higher immunoreactivity, indicating that they may contain more hormones, especially on the right side of the colon. However, the PPY- and PP-positive cells did not relate to the increased EC. and It is therefore suggested that the altered PYY in the colonic mucosa may partially contribute to the etiopathology of colonic inertia.

peptide YY pancreatic polypeptide large intestine colonic inertia 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Castro DD, Wang DA: Etiology of acquired colorectal disease. In Constipation: Etiology, Diagnosis and Treatment. Wexner SD, Bartolo DCC (eds). Oxford, Butterworth–Heinemann, 1995Google Scholar
  2. 2.
    Krishnamurthy S, Schuffler MD, Rohrmann CA: Severe idiopathic constipation is associated with a distinctive abnormality of the colonic myenteric plexus. Gastroenterology 88:26–34, 1984CrossRefGoogle Scholar
  3. 3.
    Koch TR, Carney JA, Go L, et al.: Idiopathic chronic constipation is associated with decreased colonic vasoactive intestinal peptide. Gastroenterology 94:300–310, 1988CrossRefGoogle Scholar
  4. 4.
    Milner P, Lincoln J, Crowe R, et al.: Serotonin is increased and VIP decreased in the sigmoid colon in idiopathic constipation. Gut 30:AS715, 1989Google Scholar
  5. 5.
    Wexner SD, Daniel N, Jagelman DG: Colectomy for constipation: Physiologic investigation is the key to success. Dis Colon Rectum 34:851–856, 1991CrossRefGoogle Scholar
  6. 6.
    Ehrenpreis ED, Jorge JMN, Wexner SD, et al.: Cisapride: An open label trial in patients with colonic inertia. Coloproctology 17:258–262, 1995Google Scholar
  7. 7.
    Beck DE, Fazio VW, Jagelman DG, et al.: Surgical management of colonic inertia. South Med J 82:305–309, 1989CrossRefGoogle Scholar
  8. 8.
    Tatemoto K, Carlqvist M, Mutt V: Neuropeptide Y—A novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature 296:659–660, 1982CrossRefGoogle Scholar
  9. 9.
    Tatemoto K: Neuropeptide Y: Complete aminoacid sequence of the brain peptide. Proc Natl Acad Sci USA 79:5485–5489, 1982CrossRefGoogle Scholar
  10. 10.
    Daniel EE, Collins SM, Fox JET, et al.: Pharmacology of neuroendocrine peptides. In Handbook of Physiology—The Gastrointestinal System 1. Wood JD (ed). Am Pathol Soc, Bathesda, MD, 1989Google Scholar
  11. 11.
    Lundberg JM, Tatemoto K, Terenius L, et al.: Localization of peptide YY (PYY) in gastrointestinal endocrine cells and effects on intestinal blood flow and motality. Proc Natl Acad Sci USA 79:4471, 1982CrossRefGoogle Scholar
  12. 12.
    Miyazaki K, Funakoshi A: Distribution of pancreatic polypeptide-like immunoreactivity in rat tissues. Regul Peptides 21:37–43, 1988CrossRefGoogle Scholar
  13. 13.
    Hellstrom PM, Olerup O, Tatemoto K: Neuropeptide Y may mediate effects of sympathetic nerve stimulation on colonic motility and blood flow in cat. Acta Physiol Scand 124:613–624, 1985CrossRefGoogle Scholar
  14. 14.
    Holzer P, Bartho L, Lippe IT, et al.: Effect of pancreatic polypeptide on the motility of the guinea-pig small intestine in vitro. Regul Peptides 16:305, 1986CrossRefGoogle Scholar
  15. 15.
    Garzon J, Hollt V, Sanchez-Vazquez P: Neuropeptide Y is an inhibitor of neural function in the myenteric plexus of the guinea-pig ileum. Peptides 7:623, 1986CrossRefGoogle Scholar
  16. 16.
    Holzer P, Lippe IT, Bartho L, et al.: Neuropeptide Y inhibits excitatory enteric nerves supplying the circular muscle of the guinea-pig small intestine. Gastroenterology 92:1944, 1987CrossRefGoogle Scholar
  17. 17.
    Wiley J, Owyang C: Neuropeptide Y inhibit cholinergic transmission in the isolated guinea-pig colon: Mediation through alpha-adrenergic receptors. Proc Natl Acad Sci USA 84:2047–2051, 1987CrossRefGoogle Scholar
  18. 18.
    Hellstrom PM: Mechanisms involved in colonic vasoconstriction and inhibition of motility induced by neuropeptide Y. Acta Physiol Scand 129:549–556, 1987CrossRefGoogle Scholar
  19. 19.
    Krantis A, Harding RK: Peptide YY induces nerve-mediated responses in the guinea pig intestine. Can J Physiol Pharmacol 69:1713–1718, 1991CrossRefGoogle Scholar
  20. 20.
    Wager-Page SA, Ghazali B, Anderson W, et al.: Neuropeptide Y, peptide YY, and pancreatic polypeptide modulate duodenal and colonic motility at a thoracic spinal site in rats. Peptides 13:807–813, 1992CrossRefGoogle Scholar
  21. 21.
    Wager-Page SA, Ghazali B, Anderson W, et al.: The peripheral modulation of duodenal and colonic motility in rats by the pancreatic polypeptide-fold family: Neuropeptide Y, peptide YY, and pancreatic polypeptide. Peptides 14:153–160, 1993CrossRefGoogle Scholar
  22. 22.
    Takahashi T, Yamamura T, Utsunomiya J: Human pancreatic polypeptide, neuropeptide Y and peptide YY reduce the contractile motility by depressing the release of acetylcholine from the myenteric plexus of the guinea pig ileum. Gastroenterol Japon 27:327–333, 1992CrossRefGoogle Scholar
  23. 23.
    Adrian TE, Ferri GL, Bacarese-Hamilton AJ, et al.: Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 89:1070–1077, 1985CrossRefGoogle Scholar
  24. 24.
    Preston DM, Adrian TE, Christofides ND, et al.: Positive correlation between symptoms and circulating molitin, pancreatic polypeptide and gastrin concentrations in functional bowel disorders. Gut 26:1059–1064, 1985CrossRefGoogle Scholar
  25. 25.
    Van der Sijp JRM, Kamm MA, Jeremy, et al.: Circulating gastrointestinal hormone abnormalities in patients with severe idiopathic constipation. Am J Gastroenterol 93:1351–1356, 1998CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2004

Authors and Affiliations

  • Rong Hua Zhao
    • 1
  • Khurrum M. Baig
    • 1
  • Steven D. Wexner
    • 1
  • Sherry Woodhouse
    • 1
  • Jay J. Singh
    • 1
  • Eric G. Weiss
    • 1
  • Juan J. Nogueras
    • 1
  1. 1.Department of Colorectal SurgeryCleveland Clinic FloridaWestonUSA

Personalised recommendations